

# FIG. 1

CONTIG Sequence 4 (kilobase):






FIG. 2




BEST AVAILABLE COPY

FIG. 3



**FIG. 4A**


R217A WILD TYPE Mice (N = 7)



p < 0.05 (t-test: relative to vehicle-treated controls)  
Treatment (100 mg/kg PO @ - 120 min)

**FIG. 4B**

R217A WILD TYPE Mice (N = 7)




p < 0.05 (t-test: relative to vehicle-treated controls)  
Treatment (100 mg/kg PO @ - 120 min)

+

+

# FIG. 4C

R217A HETEROZYGOTE Mice (N = 7-8)




p < 0.05 (t-test: relative to vehicle-treated controls)

Treatment (100 mg/kg PO @ - 120 min)

# FIG. 4D

R217A HETEROZYGOTE Mice (N = 7-8)



p < 0.05 (t-test: relative to vehicle-treated controls)


Treatment (100 mg/kg PO @ - 120 min)

+

+

FIG. 4E

R217A HOMOZYGOTE Mice (N = 7)




no significant differences between Vehicle  
and PGB-treated groups

Treatment (100 mg/kg PO @ - 120 min)

FIG. 4F

R217A HOMOZYGOTE Mice (N = 7)




no significant differences between Vehicle  
and PGB-treated groups

Treatment (100 mg/kg PO @ - 120 min)


+

**FIG. 5**



\*  $p < 0.05$  (t-test: relative to wild type controls)



# FIG. 6



BEST AVAILABLE COPY




+

**FIG. 7A****FIG. 7B**

+

**FIG. 8A**



**FIG. 8B**




FIG. 9

